Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence